4.6 Article

Improved short- and long-term outcome of allogeneic stem cell recipients admitted to the intensive care unit: a retrospective longitudinal analysis of 942 patients

Journal

INTENSIVE CARE MEDICINE
Volume 44, Issue 9, Pages 1483-1492

Publisher

SPRINGER
DOI: 10.1007/s00134-018-5347-x

Keywords

Hematopoietic stem cell transplantation; Intensive care; Outcome; Respiratory failure

Ask authors/readers for more resources

Intensive care unit (ICU) admission of allogeneic hematopoietic stem cell transplant (HSCT) recipients is associated with relatively poor outcome. Since longitudinal data on this topic remains scarce, we analyzed reasons for ICU admission as well as short- and long-term outcome of critically ill HSCT recipients. A total of 942 consecutive adult patients were transplanted at Hannover Medical School from 2000 to 2013. Of those, 330 patients were at least admitted once to the ICU and included in this retrospective study. To analyze time-dependent improvements, we separately compared patient characteristics as well as reasons and outcome of ICU admission for the periods 2000-2006 and 2007-2013. The main reasons for ICU admission were acute respiratory failure (ARF) in 35%, severe sepsis/septic shock in 23%, and cardiac problems in 18%. ICU admission was clearly associated with shortened survival (p < 0.001), but survival of ICU patients after hospital discharge reached 44% up to 5 years and was comparable to that of non-ICU HSCT patients. When ICU admission periods were compared, patients were older (48 vs. 52 years; p < 0.005) and the percentage of ARF as leading cause for ICU admission decreased from 43% in the first to 30% in the second period. Over time ICU and hospital survival improved from 44 to 60% (p < 0.01) and from 26 to 43% (p < 0.01), respectively. The 1- and 3-year survival rate after ICU admission increased significantly from 14 to 32% and from 11 to 23% (p < 0.01). Besides ARF and septic shock, cardiac events were especially a major reason for ICU admission. Both short- and long-term survival of critically ill HSCT patients has improved significantly in recent years, and survival of HSCT recipients discharged from hospital is not significantly affected by a former ICU stay.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Hematology

Clinical significance of mitochondrial DNA content in acute promyelocytic leukaemia

Diego A. Pereira-Martins, Juan L. Coelho-Silva, Isabel Weinhauser, Pedro L. Franca-Neto, Douglas R. Silveira, Cesar Ortiz, Amanda Moreira-Aguiar, Marinus M. Lima, Luisa C. Koury, Raul A. de Melo, Ana B. Gloria, Evandro M. Fagundes, Bruno K. Lino, Katia Pagnano, Rosane Bittencourt, Elenaide Nunes, Fabiola Traina, Lorena Figueiredo-Pontes, Armand Keating, Martin S. Tallman, Raul C. Ribeiro, Richard Dilon, Arnold Ganser, Miguel A. Sanz, Nancy Berliner, Peter Valk, Bob Lowenberg, Tiziana Ottone, Nelida Noguera, Maria T. Voso, Francesca Paoloni, Paola Fazi, Emanuele Ammatuna, Gerwin Huls, Jan Jacob Schuringa, Eduardo M. Rego, Antonio R. Lucena-Araujo

Summary: A growing body of evidence indicates that higher-than-normal mitochondrial DNA content (mtDNAc) is associated with better prognosis in acute promyelocytic leukemia (APL) patients, regardless of tumor burden. This effect is more pronounced in low-risk patients. The multivariate Cox proportional hazard model reveals that high mtDNAc is independently associated with a decreased cumulative incidence of relapse. These findings highlight the potential role of mitochondrial metabolism in APL patients treated with ATRA.

BRITISH JOURNAL OF HAEMATOLOGY (2023)

Article Oncology

Anti-EGFR-Based Therapy in Recurrent or Metastatic HNSCC - What Difference Does it Make?

Hendrik Eggers, Lea Haebel, Arnold Ganser, Viktor Gruenwald, Roland Merten, Athanasia Warnecke, Martin Durisin, Philipp Ivanyi

Summary: The application of cetuximab in palliative first-line therapy for R/M HNSCC patients can significantly improve overall survival, according to the study.

CANCER INVESTIGATION (2023)

Article Respiratory System

2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension

Marc Humbert, Gabor Kovacs, Marius M. Hoeper, Roberto Badagliacca, Rolf M. F. Berger, Margarita Brida, Jorn Carlsen, Andrew J. S. Coats, Pilar Escribano-Subias, Pisana Ferrari, Diogenes S. Ferreira, Hossein Ardeschir Ghofrani, George Giannakoulas, David G. Kiely, Eckhard Mayer, Gergely Meszaros, Blin Nagavci, Karen M. Olsson, Joanna Pepke-Zaba, Jennifer K. Quint, Goran Radegran, Gerald Simonneau, Olivier Sitbon, Thomy Tonia, Mark Toshner, Jean Luc Vachiery, Anton Vonk Noordegraaf, Marion Delcroix, Stephan Rosenkranz

EUROPEAN RESPIRATORY JOURNAL (2023)

Article Respiratory System

Sotatercept for the treatment of pulmonary arterial hypertension: PULSAR open-label extension

Marc Humbert, Vallerie McLaughlin, J. Simon R. Gibbs, Mardi Gomberg-Maitland, Marius M. Hoeper, Ioana R. Preston, Rogerio Souza, Aaron B. Waxman, Hossein-Ardeschir Ghofrani, Pilar Escribano Subias, Jeremy Feldman, Gisela Meyer, David Montani, Karen M. Olsson, Solaiappan Manimaran, Janethe de Oliveira Pena, David B. Badesch

Summary: In participants with pulmonary arterial hypertension, 24 weeks of sotatercept resulted in a significant reduction in pulmonary vascular resistance. This study reports the longer-term safety and efficacy of sotatercept in the PULSAR open-label extension, showing that sotatercept has good safety and efficacy in patients with pulmonary arterial hypertension.

EUROPEAN RESPIRATORY JOURNAL (2023)

Article Cardiac & Cardiovascular Systems

Risk stratification and response to therapy in patients with pulmonary arterial hypertension and comorbidities: A COMPERA analysis

Stephan Rosenkranz, Christine Pausch, John G. Coghlan, Doerte Huscher, David Pittrow, Ekkehard Gruenig, Gerd Staehler, Carmine Dario Vizza, Henning Gall, Oliver Distler, Marion Delcroix, Hossain A. Ghofrani, Ralf Ewert, Han -Joachim Kabitz, Dirk Skowasch, Juergen Behr, Katrin Milger, Michael Halank, Heinrike Wilkens, Hans-Juergen Seyfarth, Matthias Held, Laura Scelsi, Claus Neurohr, Anton Vonk-Noordegraaf, Silvia Ulrich, Hans Klose, Martin Claussen, Stephan Eisenmann, Kai-Helge Schmidt, Bjoern Andrew Remppis, Andris Skride, Elena Jureviciene, Lina Gumbiene, Skaidrius Miliauskas, Judith Loeffler-Ragg, Tobias J. Lange, Karen M. Olsson, Marius M. Hoeper, Christian Opitz

Summary: This study analyzed the response to PAH therapy in IPAH patients and compared the differences between patients without comorbidities, those with 1-2 comorbidities, and those with 3-4 comorbidities. The results showed that patients with comorbidities had smaller improvements in functional class, 6-minute walking distance, BNP/NT-pro-BNP, and mortality risk compared to patients without comorbidities. However, the 4-strata risk tool predicted the outcome in IPAH patients regardless of the presence of comorbidities.

JOURNAL OF HEART AND LUNG TRANSPLANTATION (2023)

Article Biophysics

Impact of chronic graft-versus-host-disease on intensive care outcome in allogeneic hematopoietic stem cell recipients

Catherina Lueck, Asterios Tzalavras, Philipp Wohlfarth, Elisabeth Meedt, Michael Kiehl, Amin T. Turki, Marius M. Hoeper, Matthias Eder, Julia Cserna, Nina Buchtele, Daniel Wolff, Peter Schellongowski, Gernot Beutel, Tobias Liebregts

Summary: Chronic graft-vs-host disease has a major impact on non-relapse mortality, but data on ICU outcomes are lacking. The study found that severe liver, intestinal, or pulmonary cGvHD is associated with worse outcomes.

BONE MARROW TRANSPLANTATION (2023)

Editorial Material Cardiac & Cardiovascular Systems

The 'Ten Commandments' of the 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension

Stephan Rosenkranz, Marion Delcroix, George Giannakoulas, Marius M. Hoeper, Gabor Kovacs, Marc Humbert

EUROPEAN HEART JOURNAL (2023)

Article Respiratory System

Early selexipag initiation and long-term outcomes: insights from randomised controlled trials in pulmonary arterial hypertension

J. Gerry Coghlan, Sean Gaine, Richard Channick, Kelly M. Chin, Camille du Roure, J. Simon R. Gibbs, Marius M. Hoeper, Irene M. Lang, Stephen C. Mathai, Vallerie V. McLaughlin, Lada Mitchell, Gerald Simonneau, Olivier Sitbon, Victor F. Tapson, Nazzareno Galie

Summary: Further understanding of when to initiate therapies in pulmonary arterial hypertension (PAH) is important to improve long-term outcomes. Post hoc analyses of GRIPHON (NCT01106014) and exploratory analyses of TRITON (NCT02558231) suggested benefit of early selexipag initiation on long-term outcomes, despite no additional benefit versus initial double combination on haemodynamic and functional parameters in TRITON. These post hoc, pooled analyses build on previous insights, further supporting selexipag use within 6 months of diagnosis, including as part of triple therapy, to delay disease progression.

ERJ OPEN RESEARCH (2023)

Article Respiratory System

AV-101, a novel inhaled dry-powder formulation of imatinib, in healthy adult participants: a phase 1 single and multiple ascending dose study

Hunter Gillies, Ralph Niven, Benjamin T. Dake, Murali M. Chakinala, Jeremy P. Feldman, Nicholas S. Hill, Marius M. Hoeper, Marc Humbert, Vallerie V. McLaughlin, Martin Kankam

Summary: AV-101, a dry powder inhaled formulation of imatinib, was well tolerated in healthy adults and significantly reduced the systemic exposure of imatinib compared with oral imatinib. An ongoing study will evaluate the safety, tolerability, and clinical benefit of AV-101 for pulmonary arterial hypertension.

ERJ OPEN RESEARCH (2023)

Article Medicine, General & Internal

Phase 3 Trial of Sotatercept for Treatment of Pulmonary Arterial Hypertension

Marius M. Hoeper, David B. Badesch, H. Ardeschir Ghofrani, J. Simon R. Gibbs, Mardi Gomberg-Maitland, Vallerie V. McLaughlin, Ioana R. Preston, Rogerio Souza, Aaron B. Waxman, Ekkehard Gruenig, Grzegorz Kopec, Gisela Meyer, Karen M. Olsson, Stephan Rosenkranz, Yayun Xu, Barry Miller, Marcie Fowler, John Butler, Joerg Koglin, Janethe de Oliveira Pena, Marc Humbert

Summary: This study confirms that in patients with stable background therapy, sotatercept can significantly improve the exercise capacity of patients with pulmonary arterial hypertension compared to placebo.

NEW ENGLAND JOURNAL OF MEDICINE (2023)

Article Respiratory System

Highlights from the International Chronic Thromboembolic Pulmonary Hypertension Congress 2021

Gerald Simonneau, Elie Fadel, Anton Vonk Noordegraaf, Mark Toshner, Irene M. Lang, Frederikus A. Klok, Micheal C. McInnis, Nicholas Screaton, Michael M. Madani, Guillermo Martinez, Kiran Salaunkey, David P. Jenkins, Hiromi Matsubara, Philippe Brenot, Marius M. Hoeper, Hossein A. Ghofrani, Xavier Jais, Christoph B. Wiedenroth, Stefan Guth, Nick H. Kim, Joanna Pepke-Zaba, Marion Delcroix, Eckhard Mayer

Summary: Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare complication of acute pulmonary embolism caused by persistent obstruction of the pulmonary arteries. It requires timely and accurate diagnosis through imaging and haemodynamic assessment. Optimal therapy should be determined by an experienced multidisciplinary CTEPH team. This report summarizes current knowledge and key messages from the International CTEPH Conference, covering various aspects of the disease.

EUROPEAN RESPIRATORY REVIEW (2023)

Article Hematology

AML in the elderly-A global view

Peter Hokland, Isolda I. Fernandez, Sylvie D. Freeman, Bjorn T. Gjertsen, Jie Jin, Vidh Murthy, Masamitsu Yanada, Arnold Ganser

BRITISH JOURNAL OF HAEMATOLOGY (2023)

Letter Cardiac & Cardiovascular Systems

Long-Term Effects of Sotatercept on Right Ventricular Function

Mardi Gomberg-Maitland, Vallerie V. Mclaughlin, David B. Badesch, Hossein-Ardeschir Ghofrani, Marius M. Hoeper, Marc Humbert, Ioana R. Preston, Rogerio Souza, Aaron B. Waxman, Janethe de Oliveira Pena, Jonathan T. Lu, Solaiappan Manimaran, J. Simon R. Gibbs

JACC-HEART FAILURE (2023)

Article Oncology

MRD as Biomarker for Response to Donor Lymphocyte Infusion after Allogeneic Hematopoietic Cell Transplantation in Patients with AML

Katrin Teich, Michael Stadler, Razif Gabdoulline, Jyoti Kandarp, Clara Wienecke, Bennet Heida, Piroska Klement, Konstantin Buttner, Letizia Venturini, Martin Wichmann, Wolfram Puppe, Christian Schultze-Florey, Christian Koenecke, Gernot Beutel, Matthias Eder, Arnold Ganser, Michael Heuser, Felicitas Thol

Summary: Donor lymphocyte infusions (DLIs) can be used to prevent or treat relapse in acute myeloid leukemia (AML) patients after allogeneic hematopoietic cell transplantation (alloHCT). Measurable residual disease (MRD) is a valuable biomarker for predicting the response and outcome of DLI treatment. This retrospective study showed that MRD status before and after DLI treatment is prognostic for event-free survival, overall survival, cumulative incidence of relapse, and relapse-free survival.

CANCERS (2023)

No Data Available